Amgen, Inc. (AMGN): The Only True Biotech Dividend Stock

All three have repurchased shares over the last few years. Celgene, for example, recently completed a $2.5 billion stock repurchase and reupped for another $3 billion.

While I’m sure there are a lot of dividend investors that would like to have more options for biotech dividend stocks, at least the companies aren’t hoarding shareholders’ cash.

The article The Only True Biotech Dividend Stock originally appeared on and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celgene and Gilead Sciences.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.